Moody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Moody Aldrich Partners LLC lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 32.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,223 shares of the biopharmaceutical company's stock after selling 4,356 shares during the quarter. Moody Aldrich Partners LLC's holdings in Madrigal Pharmaceuticals were worth $2,134,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC lifted its position in Madrigal Pharmaceuticals by 454.5% during the 4th quarter. Global Retirement Partners LLC now owns 122 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 100 shares during the period. Montag A & Associates Inc. lifted its position in Madrigal Pharmaceuticals by 223.3% during the 3rd quarter. Montag A & Associates Inc. now owns 194 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 134 shares during the period. Russell Investments Group Ltd. acquired a new stake in Madrigal Pharmaceuticals during the 1st quarter worth approximately $55,000. Osaic Holdings Inc. lifted its position in Madrigal Pharmaceuticals by 30.1% during the 2nd quarter. Osaic Holdings Inc. now owns 333 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 77 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Madrigal Pharmaceuticals by 95.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 468 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 228 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on MDGL shares. Citigroup increased their price objective on Madrigal Pharmaceuticals from $382.00 to $389.00 and gave the stock a "buy" rating in a research report on Friday, March 15th. TD Cowen raised their price target on Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the company an "outperform" rating in a report on Friday, March 15th. JMP Securities raised their price target on Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the company an "outperform" rating in a report on Friday, March 15th. B. Riley raised Madrigal Pharmaceuticals from a "sell" rating to a "neutral" rating and raised their price target for the company from $155.00 to $270.00 in a report on Friday, March 15th. Finally, HC Wainwright raised their price target on Madrigal Pharmaceuticals from $405.00 to $425.00 and gave the company a "buy" rating in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $377.40.

Madrigal Pharmaceuticals Price Performance

MDGL stock traded down $4.67 during midday trading on Wednesday, hitting $244.67. 226,258 shares of the stock were exchanged, compared to its average volume of 546,308. The stock's 50-day moving average price is $240.93 and its 200-day moving average price is $206.38. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of -12.27 and a beta of -0.47. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $119.76 and a fifty-two week high of $322.67. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.38 and a current ratio of 5.38.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by ($0.42). During the same period in the previous year, the business earned ($4.98) earnings per share. Research analysts predict that Madrigal Pharmaceuticals, Inc. will post -21.48 earnings per share for the current year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CMO Rebecca Taub sold 2,676 shares of the firm's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $245.99, for a total transaction of $658,269.24. Following the completion of the transaction, the chief marketing officer now owns 458,999 shares of the company's stock, valued at $112,909,164.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Madrigal Pharmaceuticals news, CMO Rebecca Taub sold 2,676 shares of the firm's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $245.99, for a total transaction of $658,269.24. Following the completion of the transaction, the chief marketing officer now owns 458,999 shares of the company's stock, valued at $112,909,164.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul A. Friedman sold 18,710 shares of the firm's stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $242.96, for a total value of $4,545,781.60. Following the transaction, the director now directly owns 185,735 shares of the company's stock, valued at approximately $45,126,175.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,496 shares of company stock valued at $31,362,420. Corporate insiders own 23.92% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.